Company Overview and News
With over five thousand years of history and a population of nearly 1.4 billion, everything about China is massive. China was shrouded in isolation for most of the 20th century, and just 40 years ago reopened its borders to the world.
0941 CHLKF CHL SPG EOG
U.S.-based telecom sector stocks have been soaring amid progress towards advancing 5G (next generation) technology and despite global competition.
XLNX K3ED CHLKF CHJHF TMUS CMCSA CHA 0941 0762 CHL CHUFF ADI VZ 0728 CCI CHU QCOM
Qualcomm Technologies, Inc, a subsidiary of QUALCOMM Incorporated (QCOM - Free Report) , China Mobile Research Institute and China Mobile IoT (“CMIoT”) Company Limited recently announced new roadside units (RSUs) for 3rd Generation Partnership Project (3GPP) Release 14 LTE-V2X direct communication (PC5). The system is based on the Qualcomm 9150 Cellular Vehicle-to-Everything (C-V2X) chipset solution.
RBBN 0941 CHLKF CHL UBNT QCOM
Hong Kong/Beijing: Long before he became China’s most globally prominent business figure, Jack Ma was just an English teacher trying to persuade his friends that they would one day buy things over the internet.
0941 BABA CHLKF CHL 0700 TWTR
We performed channel checks in relation to initial online and offline preorder data for the new iPhones that were announced on September 12. Compared to the last few years, our research tells us that first day preorders in China for the iPhone XS and iPh- one XS Max is weaker than previous iPhone launches.
0941 CHLKF CHL
The SPDR S&P Emerging Markets Dividend ETF (EDIV - Free Report) made its debut on 02/23/2011, and is a smart beta exchange traded fund that provides broad exposure to the Broad Emerging Market ETFs category of the market.
0941 EDIV VODAF CHLKF CHL VDMCY IEMG VWO
His vision changed China. As Ma makes plans to leave Alibaba Group Holding Ltd, his legacy will be an enduring one. He did far more than just create and build an e-commerce juggernaut into the most valuable company in Asia, impressive as that may be.
0941 BABA CHLKF CHL 0700
2018-09-06 seekingalpha - 2
5G will be 10 times faster and allow you to be online wherever you are, which should mean portable devices will increase further in popularity.
JD FB TWX MOMO NFLX VZA SWKS KT AAPL CSCO NOK INTC BIDU DIS CHLKF VOD VOD TMUSP TMUS BC94 SMSN TWC 0941 S CHL VODPF GOOGL VZ MSFT QCOM SMSD
Designed to provide broad exposure to the Broad Developed World ETFs category of the market, the WisdomTree International LargeCap Dividend Fund (DOL - Free Report) is a smart beta exchange traded fund launched on 06/16/2006.
0941 CHLKF CHL NVS
Two of China’s three largest wireless carriers are reportedly discussing a merger. China Unicom (Hong Kong) Ltd. (NYSE: CHU) and China Telecommunications Corp. Ltd. (NYSE: CHA) are both state-controlled wireless carriers and the second- and third-largest wireless carriers in the country with a combined total of more than 590 million subscribers. China Mobile Ltd. (NYSE: CHL), the country’s largest wireless carrier with more than 900 million subscribers, is also a state-controlled enterprise.
0941 K3ED 0762 CHLKF CHL CHJHF CHUFF CHA 0728 CHU
BEIJING (Sept 4): China is exploring a merger between two of the nation’s three wireless carriers to speed up the development of 5G mobile services amid a race with the US over the technology, according to people familiar with the matter.
K3ED CHLKF CHJHF CHA 0941 0762 CHL CHUFF AVGO 0728 BRCM CHU QCOM
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...